Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
HIV Infections
Interventions
DRUG

Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h

Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h

DRUG

Nevirapine (Viramune): 1 comp (200mg)/12h

Nevirapine (Viramune): 1 comp (200mg)/12h

Trial Locations (24)

12004

Hospital General de Castellón, Castelló

15706

Hospital C. Universitario de Santiago, Santiago

17230

Hospital de Palamós, Palamós

17600

Hospital de Figueres, Figueres

28040

Hospital C. San Carlos, Madrid

29010

Hospital C. Universitario Virgen de la Victoria, Málaga

29600

Hospital Costa del Sol, Marbella

30071

Hospital Nuestra Señora del Rosell, Cartagena

33006

Hospital Central de Asturias, Asturias

36204

Hospital Xeral Cies de Vigo, Vigo

39008

Hospital Marqués de Valdecilla, Santander

43007

Hospital Universitario Joan XXIII de Tarragona, Tarragona

43201

Hospital Sant Joan de Reus, Reus

46010

Hospital Clínico de Valencia, Valencia

46015

Hospital Arnau de Vilanova, Valencia

03010

Hospital General Universitario de Alicante, Alicante

03203

Hospital General Universitario de Elche, Elche

07800

Hospital Can Mises, Ibiza Town

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08025

Hospital de Sant Pau, Barcelona

08304

Hospital de Mataró, Barcelona

08400

Hospital de Granollers, Granollers

08221

Mutua de Terrassa, Terrassa

07701

Hospital Virgen del Toro, Mahon

All Listed Sponsors
collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Germans Trias i Pujol Hospital

OTHER

NCT00335686 - Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients | Biotech Hunter | Biotech Hunter